ACADIA Pharmaceuticals (FRA:DR6) EBIT: €69.4 Mil (TTM As of Mar. 2026)


FRA:DR6 ACADIA Pharmaceuticals Inc FRA:DR6
76 GF Score
Price €20.55
GF Value €21.67
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals EBIT?

ACADIA Pharmaceuticals FRA:DR6 +3.92% 76 EBIT is €69.4 Mil as of Mar. 2026. GuruFocus rates FRA:DR6 with a GF Score™ of 76/100 and a GF Value™ of €21.67 (Fairly Valued). The stock has 8 warning signs investors should review.

ACADIA Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-4.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €69.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ACADIA Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was -3.05%. ACADIA Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -32.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ACADIA Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.42%.

ACADIA Pharmaceuticals  (FRA:DR6) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ACADIA Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-15.972 * ( 1 - 8.65% )/( (477.637 + 477.855)/ 2 )
=-14.590422/477.746
=-3.05 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1335.823 - 187.796 - ( 700.012 - max(0, 236.655 - 907.045+700.012))
=477.637

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1388.524 - 226.893 - ( 736.511 - max(0, 264.278 - 948.054+736.511))
=477.855

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

ACADIA Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-15.972/( ( (46.855 + max(-42.552, 0)) + (52.701 + max(-53.81, 0)) )/ 2 )
=-15.972/( ( 46.855 + 52.701 )/ 2 )
=-15.972/49.778
=-32.09 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(103.724 + 29.608 + 50.836) - (187.796 + 0 + 38.924)
=-42.552

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(117.078 + 27.312 + 55.879) - (226.893 + 0 + 27.186)
=-53.81

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ACADIA Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=69.391/2872.262
=2.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals EBIT Related Terms

ACADIA Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals EBIT Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -150.84 -211.08 -67.29 80.49 89.51

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.84 28.07 30.46 14.85 -3.99

FRA:DR6 vs EWTX, CRNX, VKTX: EBIT Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's EV-to-EBIT falls into.


FRA:DR6
76GF Score
ACADIA Pharmaceuticals Inc FRA:DR6
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €69.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €69.4 Mil mean?
ACADIA Pharmaceuticals (FRA:DR6) has a EBIT of €69.4 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ACADIA Pharmaceuticals.
Is ACADIA Pharmaceuticals' EBIT too high?
ACADIA Pharmaceuticals' current EBIT is €69.4 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' EBIT compare to EWTX and CRNX?
ACADIA Pharmaceuticals' EBIT of €69.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ACADIA Pharmaceuticals. ACADIA Pharmaceuticals's current EBIT is €69.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Fairly Valued. The stock's GF Value™ is €21.67, compared to a current price of €20.55 — trading 5.2% below its estimated fair value. The current EBIT is €69.4 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current EBIT is €69.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of €20.55 is trading 5.2% below its estimated GF Value™ of €21.67. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:DR6:

  • EBIT: €69.4 Mil
  • GF Value™: €21.67 vs. price of €20.55 (5.2% below fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USAACAD:Mexico
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for FRA:DR6

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.55
Price
€21.67
GF Value